Facebook
Twitter
LinkedIn
Forward
PARP-inhibitors in Prostate Cancer: A Three-PARP Series for the Urologic Care Team (2023)
COMPLIMENTARY CME VIRTUAL COURSES!
The American Urological Association (AUA) has developed a series of live virtual and on-demand educational offerings to further address the identified educational gaps and barriers in advanced prostate cancer care. Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessments, a three-part educational series to update urologists and advanced practice providers (APPs) on PARP-inhibitor (PARPi) treatment in advanced prostate cancer is being offered.
Live virtual courses will be held monthly from November 2023 – January 2024. Topics will focus on Precision Medicine, Genetic Testing, and Management of Adverse Events. Following each of the live virtual activities, the courses will be captured and posted on AUA’s online learning system, AUAUniversity, and the AUAUniversity YouTube channel for on-demand viewing for up to one year. Additionally, the recordings will be released as three individual episodes on the very successful AUAUniversity Podcast.
Participants will be asked to complete a Pre-work Library in advance of attending the live virtual courses. The Pre-work Library will include relevant AUA Clinical Guidelines, journal articles and the webcast/podcast of “The Role of PARP Inhibitors in Advanced Prostate Cancer: An AUA/SUO Joint Symposium” presented at the 2023 AUA Annual Meeting.
Join us for:
PARPi: Precision Medicine in Advanced Prostate Cancer | November 14, 2023 | 7:00-8:00 p.m. ET
A multidisciplinary panel, including a urologist, oncologist, and APP, will present the latest advances in PARPi. The expert faculty will engage in an interactive, case-based discussion amongst each other and engage with the learners through Q&A
PARPi: Genetic Testing in Advanced Prostate Cancer - When and Who to Test | December 13, 2023 | 7:00-8:00 p.m. ET
A moderator and two subject matter experts, including a genetic counselor and pathologist, will update the urologic care team on the importance of genetic testing of prostate cancer patients and how to interpret these tests.
PARPi: Management of Adverse Events | January 16, 2024 | 7:00-8:00 p.m. ET
This offering will update the urologic care team on the latest developments in PARPi, focusing on the identification and management of adverse events.
ACKNOWLEDGEMENT
This educational activity is supported by an independent educational grant from:
- Pfizer, Inc.
Target Audience
- Urologist
- Resident
- Advanced Practice Provider (Nurse Practitioners, Physician Assistants, Nurse Navigators)
Learning Objectives
PARPi: Precision Medicine in Advanced Prostate Cancer
At the conclusion of this activity, the learner will:
- Describe the mechanism of action of PARP inhibitors and the differences among drugs in this class.
- Describe the role of PARPi treatment alone and in combination with other cancer based therapies.
- Discuss existing clinical trial data assessing the efficacy of PARPi in advanced prostate cancer and ongoing late phase trials for PARP inhibitors.
- Recognize the need for a multidisciplinary team to provide care for patients with advanced prostate cancer.
PARPi: Genetic Testing in Advanced Prostate Cancer - When and Who to Test
At the conclusion of this activity, the learner will:
- Review recommended criteria for genetic testing of prostate cancer patients, currently available gene panels, and options for testing these men.
- Explain the importance of testing for germline and somatic mutations and their implications for utilizing PARPi.
- Describe work flows for genetic testing and utilization of genetic counselors.
- Describe the genetic counseling process and the importance of pre-test counseling to discuss the benefits, limitations, and potential implications of germline testing for patients and their families.
PARPi: Management of Adverse Events
At the conclusion of this activity, the learner will:
- Identify approved PARPi for prostate cancer and patients who may benefit from PARPi based therapy.
- Evaluate available clinical safety and efficacy data for PARPi.
- Describe indications and contraindications for PARPi in patients with advanced prostate cancer.
- Identify how to manage adverse events that patients may experience while taking a PARPi.
ACCREDITATION:
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION:
The American Urological Association designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
OTHER LEARNERS:
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
If you are interested in participating in one or more of the live webinars, please click on the name of each course above and complete the registration process for each one, outlined under the “Take Course” tab. Each course has its' own distinct ZOOM link that you will need to join the live virtual course.
Registration for these Live Virtual Courses is complimentary.
Attendee Information & Policies
AUA Anti-Harassment Policy
AUA Commitment: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress.
Reporting Harassment: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at jskorepa@AUAnet.org or Maureen E. Cones, Esq., AUA General Counsel, at mcones@auanet.org or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly.
The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA).
Consent to Use of Photographic Images: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities.
Audio, Video, Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the AUA.
Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, a written request should be submitted at least one month in advance. For additional assistance with your request please call 1-800-908-9414.